Omega-3 lipids for intestinal failure associated liver disease

Semin Pediatr Surg. 2009 Nov;18(4):239-45. doi: 10.1053/j.sempedsurg.2009.07.005.

Abstract

Intestinal failure associated liver disease (IFALD) is one of the most common and devastating complications in infants with intestinal failure. Although multifactorial, its pathophysiology is clearly related to the administration of parenteral nutrition (PN), with a recent focus on the role of PN lipid emulsions. This paper will review the evidence for the use of omega-3 fatty acid PN lipid emulsions, which are proposed to have efficacy in the treatment of IFALD. Mechanisms explaining their effects will be considered as will future research directions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Fat Emulsions, Intravenous / pharmacology*
  • Fat Emulsions, Intravenous / therapeutic use
  • Fatty Acids, Omega-3 / pharmacology*
  • Fatty Acids, Omega-3 / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Intestinal Diseases / complications*
  • Intestinal Diseases / diagnosis
  • Intestinal Diseases / therapy
  • Liver Diseases / diagnosis
  • Liver Diseases / etiology*
  • Liver Diseases / therapy*
  • Parenteral Nutrition*
  • Treatment Outcome

Substances

  • Fat Emulsions, Intravenous
  • Fatty Acids, Omega-3